Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (the pharmacodynamic evaluation of Angiomax, clopidogrel with or without INtegrilin [DEACON] study)

American Journal of Cardiology

Volumn 95, Issue 12, 2005, Pages 1453-1456

  Saucedo, Jorge F ^a   Aude, Wady ^b   Pacheco, Rebecca ^b   Thorn, Brett ^b   Matin, Zakaria ^b   Husain, Khawaja ^b   Garza, Luis ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HUMAN; LABORATORY TEST; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREOPERATIVE CARE; RECOMBINANT PROTEINS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 20444470580     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.02.012     Document Type: Article

References (18)

1. G.V.R. Born, M.J. Cross The aggregation of blood platelets J Physiol (Lond) 168 1963 178 195
2. B.S. Coller, J.D. Folts, S.R. Smith, L.E. Scudder, R. Jordan Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet glycoprotein IIb/IIIa receptor Correlation with bleeding time, platelet aggregation, and blockade of glycoprotein IIb/IIIa receptors Circulation 80 1989 1766 1774
3. J.E. Tcheng, S.G. Ellis, B.S. George, D.J. Kereiakes, N.S. Kleiman, J.D. Talley, A.L. Wang, H.F. Weisman, R.M. Califf, E.J. Topol Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty Circulation 90 1994 1757 1764
4. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II Lancet 349 1997 1422 1428
5. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomised, placebo-controlled trial Lancet 356 2000 2037 2044
6. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
7. E.J. Topol, D.J. Moliterno, H.C. Herrmann, E.R. Powers, C.L. Grines, D.J. Cohen, E.A. Cohen, M. Bertrand, F.J. Neumann, G.W. Stone TARGET Investigators Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 244 2001 1888 1894
8. S.S. Kabbani, A. Aggarwal, E.F. Terrien, P.M. DiBattiste, B.E. Sobel, D.J. Schneider Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions Am J Cardiol 89 2002 647 650
9. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
10. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
11. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet 352 1998 87 92
12. R.A. Harrington, N.S. Kleiman, K. Kottke-Marchant, A.M. Lincoff, J.E. Tcheng, K.N. Sigmon, D. Joseph, G. Rios, K. Trainor, D. Rose Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention Am J Cardiol 76 1995 1222 1227
13. D.J. Kereiakes, T. Lorenz, J.J. Young, G. Kukielka, M.N. Mueller, L. Nanniazzi-Alaimo, D.R. Phillips Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban J Thromb Thrombolysis 12 2001 123 127
14. J.E. Tcheng, J.D. Talley, J.C. O'Shea, I.C. Gilchrist, N.S. Kleiman, C.L. Grines, C.J. Davidson, A.M. Lincoff, R.M. Califf, L.K. Jennings Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study) Am J Cardiol 88 2001 1097 1102
15. J.C. O'Shea, G.E. Hafley, S. Greenberg, V. Hasselblad, T.J. Lorenz, M.M. Kitt, J. Strony, J.E. Tcheng ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention-the ESPRIT trial a randomized controlled trial JAMA 285 2001 2468 2473
16. J.C. O'Shea, C.E. Buller, W.J. Cantor, A.B. Chandler, E.A. Cohen, D.J. Cohen, I.C. Gilchrist, N.S. Kleiman, M. Labinaz, M. Madan ESPRIT Investigators Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention JAMA 287 2002 618 621
17. D.J. Kereiakes, N.S. Kleiman, J. Ambrose, M. Cohen, S. Rodriguez, T. Palabrica, H.C. Herrmann, J.M. Sutton, W.D. Weaver, D.B. McKee Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty J Am Coll Cardiol 27 1996 536 542
18. S.R. Steinhubl, J.D. Talley, G.A. Braden, J.E. Tcheng, P.J. Casterella, D.J. Moliterno, F.I. Navetta, P.B. Berger, J.J. Popma, G. Dangas Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention results of the GOLD (AU-Assessing Ultegra) multicenter study Circulation 103 2001 2572 2578